In a significant advancement for medical imaging technology, Koninklijke Philips N.V. has secured both US Food and Drug Administration (FDA) 510(k) clearance and the CE mark in Europe for its latest innovation: Elevate Plus. This comprehensive upgrade package is designed to transform the operational capabilities of Philips’ flagship EPIQ Elite and Affiniti ultrasound systems. By integrating advanced artificial intelligence (AI) and automated workflow features, Philips aims to address the persistent challenges of clinical variability, staff burnout, and the increasing demand for high-throughput diagnostic imaging.
The Core Innovation: Elevate Plus
The healthcare sector is currently grappling with a dual crisis: a shortage of experienced sonographers and an exponential increase in the volume of diagnostic imaging requests. Elevate Plus enters this landscape as a solution intended to standardize routine examinations, ensuring that diagnostic quality remains high regardless of the operator’s experience level.
At its core, Elevate Plus is not merely a software update but a fundamental redesign of the user experience. By automating repetitive tasks, the platform allows clinicians to focus on complex patient assessments rather than the technical minutiae of image optimization. This shift is expected to reduce the need for repeat scanning—a major pain point in hospital efficiency—by delivering consistent, high-quality images on the first attempt.
Chronology of the Development and Regulatory Milestones
The journey to the release of Elevate Plus reflects Philips’ long-term strategy of embedding AI into the "point-of-care" clinical environment.
- Initial Research and Development: Over the past several years, Philips focused on identifying the most time-consuming aspects of ultrasound examinations. Clinical studies confirmed that manual measurements and subjective image adjustments were the primary drivers of workflow bottlenecks.
- AI Integration Strategy: Philips moved away from simple image processing to deep-learning-based automation. The collaboration with specialized AI developers, such as the integration of Koios AI, was a pivotal step in moving decision-support tools from off-cart, external software to an on-cart, real-time clinical environment.
- Regulatory Submission: Throughout 2025, Philips worked closely with regulatory bodies to validate the safety and efficacy of these automated measurement tools.
- The Approval Wave: In June 2026, the company achieved its dual-market goal, securing FDA 510(k) clearance and the European CE mark simultaneously. This simultaneous approval allows for a rapid, global rollout across North American and European healthcare networks.
Supporting Data and Clinical Efficacy
The efficacy of Elevate Plus is grounded in robust clinical validation. Central to the upgrade is the "Auto Measure Abdomen" tool, which utilizes deep learning to identify anatomical landmarks and perform routine measurements.
Clinical performance data provided by Philips reveals that the Auto Measure Abdomen application achieves an accuracy rate exceeding 93% when measured against the gold standard of manual readings performed by experienced clinical radiologists. By removing the "operator effect"—the tendency for different clinicians to produce slightly different measurements—the system ensures a uniform standard of care.
Furthermore, the integration of Koios AI for lesion classification represents a significant leap in diagnostic confidence. By leveraging large datasets of pathology-confirmed cases, the system provides real-time support for Bi-RADS (Breast Imaging-Reporting and Data System) and Ti-RADS (Thyroid Imaging-Reporting and Data System) assessments. Historically, these tools required clinicians to export images to a secondary workstation, increasing the time per patient and the risk of diagnostic delay. By bringing this decision support "on-cart," Philips has effectively collapsed the diagnostic cycle, allowing for immediate risk assessment while the patient is still in the exam room.
Technical Enhancements: Sharper Detail, Better Flow
Beyond AI automation, Elevate Plus introduces two critical imaging functions aimed at improving visual clarity:
- XRes Pro+: This technology utilizes advanced algorithms to refine tissue detail and provide sharper anatomical boundaries. By reducing speckle noise and enhancing contrast, it allows clinicians to distinguish between healthy and diseased tissue with greater precision, which is particularly vital in challenging body habitus cases.
- Super Res MVI Pro: Microvascular imaging has long been a "holy grail" for ultrasound. This new function enhances the visualization of low-velocity blood flow in small vessels. For clinicians monitoring tumor angiogenesis or complex organ perfusion, this provides a level of clarity that was previously restricted to higher-end, more expensive specialized systems.
Official Responses and Strategic Vision
Jie Xue, Chief Business Leader of Precision Diagnosis at Philips, underscored the strategic importance of this launch. In a formal statement following the regulatory approval, Xue emphasized that the technology is a direct response to the pressures facing modern healthcare teams.
"Elevate Plus underscores our commitment to advancing AI-powered ultrasound to help clinicians deliver more consistent, efficient, and confident ultrasound care to patients," Xue noted. "By combining intelligent imaging with AI-powered workflow automation across our ultrasound platform, Elevate Plus is designed to reduce variability, streamline routine exams, and support faster, more informed clinical decisions as care teams face growing demand."
The message from Philips leadership is clear: the future of ultrasound is not just about clearer pictures, but about a more intelligent platform that acts as a "clinical assistant" to the sonographer.
Implications for Healthcare Providers
The implications of the Elevate Plus rollout are manifold, impacting stakeholders from hospital administrators to frontline clinicians and, ultimately, patients.
Operational Efficiency
For hospital administrators, the primary benefit is throughput. In departments like radiology and emergency medicine, every minute saved on a routine scan increases the hospital’s capacity to see more patients. The reduction in inter-operator variability also decreases the likelihood of inconclusive scans that necessitate costly follow-up appointments.
Clinical Confidence and Burnout Reduction
For sonographers and radiologists, the technology serves as a tool against burnout. By automating the most tedious aspects of the job—such as tracing structures or performing repetitive measurements—the system allows the clinician to engage more deeply with the patient. It shifts the role of the sonographer from a data-collector to a diagnostic partner.
Enhanced Patient Outcomes
Ultimately, the goal is improved patient outcomes. The ability to perform rapid, accurate risk assessments for breast and thyroid lesions on the spot reduces patient anxiety and facilitates faster referrals to surgery or oncology when necessary. In the context of microvascular imaging, the ability to visualize blood flow more accurately can lead to earlier detection of complications in transplant patients or chronic disease management.
Conclusion: Setting a New Standard
As the healthcare industry continues to embrace digital transformation, the integration of AI into point-of-care ultrasound is no longer a luxury but a necessity. With the clearance of Elevate Plus, Philips has set a new benchmark for what is expected from a modern ultrasound system.
By bridging the gap between raw imaging power and intelligent, AI-assisted decision support, Philips is ensuring that their EPIQ Elite and Affiniti systems remain at the forefront of clinical practice. As the technology is deployed across hospitals in the US and Europe, the medical community will be watching closely to see how these efficiencies translate into long-term improvements in patient care and operational sustainability. The era of "smart" ultrasound has arrived, and it promises a future where precision is the standard, not the exception.
About the Author
